 - Anticipated or documented prolonged neutropenia and likely to last for at least 7 days due to: a standard intensive chemotherapy, anthracycline-based or other accepted regimen excluding any investigational agent for a new diagnosis of acute myelogenous leukemia AML; bchemotherapy for AML in first relapse; or c therapy for myelodysplastic syndromes in transformation to AML or other diagnoses of secondary AML therapy related, antecedent hematological disorders or chronic myelogenous leukemia in blast crisis 